Curtis Hougland, Founder & Philip Storer, PartnerBut unless the industry fundamentally changes how it identifies patients, many of those therapies will never reach the finish line.
Artificial intelligence can analyze biological systems, identify promising targets and move potential molecules toward clinical development faster than traditional research methods. Yet as more therapies enter development, more trials will compete for the same limited and already visible patient populations.
Drug discovery is accelerating. Patient discovery isn’t. AI must also solve patient recruitment.
Clinical trial recruitment still relies largely on site databases, physician referrals, electronic health records, registries, advocacy organizations and patients who actively raise their hands.
Those methods remain important. They are doing what they were designed to do. But they primarily search among patients who are already visible within the healthcare and clinical research ecosystem. Making these channels more efficient may improve recruitment performance. It does not necessarily expand the available patient population.
That limitation is becoming a critical constraint on scientific progress. A promising therapy cannot be evaluated, approved or delivered if its clinical trial cannot enroll. Recruitment is no longer merely a supporting operational function. Increasingly, it is the bottleneck that determines whether scientific advances reach patients at all.
The next challenge is finding net-new patients, people who may qualify for a study but are absent from the databases, referral networks and digital audiences sponsors typically use.
AI offers a way to search beyond those boundaries.
The public internet is the largest and most continuously expanding collection of human signals ever created. Disease language, community relationships, geography, peer conversations, online behavior and patterns of engagement can all help reveal where potential patient populations may exist.
-
AI is helping the industry create more therapies. Its next major contribution may be ensuring those therapies reach the patients required to study them.
The task is not simply to collect more data. It is to interpret fragmented public signals, identify meaningful patient communities and translate complex trial criteria into a practical patient-discovery model.
Companies such as Seen & Heard Health are applying AI, graph analysis and human review to locate patients outside established recruitment channels. That includes people who may be more geographically, economically and socially diverse than the usual clinical trial “hand-raisers.”
The distinction matters. Clinical research does not need another source of loosely qualified leads. Sponsors need patients who can be identified, engaged, verified and supported as they move toward screening and enrollment.
This emerging model begins with the broadest addressable audience on earth. It then narrows that audience through observable signals and protocol-based criteria before initiating trusted human engagement. Each accepted or rejected candidate can further refine the discovery process.
AI is helping the industry create more therapies. Its next major contribution may be ensuring those therapies reach the patients required to study them.
Rethinking Patient Identification in Clinical Trial Recruitment
Clinical development timelines are no longer constrained by discovery alone; they are increasingly dictated by the ability to identify and enroll the right patients at the right moment. Breakthrough therapies continue to advance, yet enrollment delays persist as a structural bottleneck. A large proportion of trials still fail to meet recruitment targets, not due to lack of interest, but because conventional outreach methods repeatedly surface the same limited patient pools. Referral networks, registries, digital campaigns and electronic health records offer reach, yet struggle to extend beyond already visible populations.
This imbalance introduces a deeper issue than speed alone. Trial viability now depends on accessing patients who are not actively signaling participation intent, those who remain outside institutional touchpoints or who exhibit low trust in healthcare systems. Recruitment strategies that rely on explicit engagement signals tend to exclude individuals who do not self-identify or who exist in fragmented data environments. The consequence is not only slower enrollment but also reduced diversity and limited representation across geography, socioeconomic background and disease profiles.
A shift is underway toward leveraging broader data ecosystems, particularly unstructured data generated through everyday digital behavior. Text, images and interaction patterns offer probabilistic indicators of health status, yet extracting meaningful signals requires systems that can interpret nuance rather than rely on predefined categories. The challenge is not access to data, but the ability to structure and refine it into actionable cohorts aligned with precise inclusion and exclusion parameters. Systems that continuously learn from recruitment outcomes, improving candidate selection with each iteration, demonstrate clear advantages in environments where criteria evolve.
"Systems that operate across therapeutic areas and geographies, without relying on pre-existing patient pools, enable scalable enrollment, especially for rare or dispersed populations. Seen & Heard Health applies machine learning to advance this model in clinical trials."
Precision in defining eligibility remains central. Recruitment effectiveness hinges on translating clinical protocols into data-driven search frameworks that account for comorbidities, geography, demographic variables and behavioral signals. Static filtering approaches struggle under this complexity. Adaptive systems that refine candidate pools based on feedback loops allow recruitment strategies to become more targeted, reducing inefficiencies and improving match quality. This dynamic refinement also shortens the distance between identification and enrollment, which is critical in time-sensitive trials.
Equally important is the method of engagement. Traditional outreach channels face diminishing response rates as trust in institutional messaging declines. Patients increasingly respond to communication that reflects familiar language, peer context and situational relevance. Recruitment approaches that align messaging with patient context, rather than relying on broad campaigns, are better positioned to convert awareness into participation. Engagement is no longer a downstream activity but an integrated component of the identification process.
These shifts point to a model where recruitment platforms are expected to unify data ingestion, cohort refinement and patient communication within a single framework. Systems that can operate across therapeutic areas and geographies without reliance on pre-existing patient pools offer scalability, particularly for trials involving rare conditions or dispersed populations.
Seen & Heard Health reflects this direction through a focused application of machine learning designed specifically for clinical trial enrollment. It applies trained models to both structured inputs, such as health records and large volumes of publicly available unstructured data, enabling identification of patients beyond conventional databases.
Its approach centers on refining inclusion and exclusion criteria into continuously improving search parameters, allowing candidate selection to become more accurate over time. The platform also integrates context-aware engagement, aligning outreach with patient behavior and communication preferences. Having contributed to enrollment across thousands of patients, it demonstrates an ability to support trials that struggle to reach completion through traditional channels.
...Read more
